| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 42.0 | 37.3 |
| Gross profit | 21.9 | 17.1 |
| Net income | -1.7 | -9.0 |
| EPS (diluted, $ a share) | $-0.02 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +12.5% |
|---|---|
| Gross margin | 52.2% |
| Operating margin | 1.3% |
10-Q filed with the SEC, NASDAQ: STIM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Neuronetics, Inc.: key numbers
- Share price
- $1.25Close, Nov 16
- Market cap
- $97.2M
- Shares outstanding
- 77.73MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neuronetics, Inc.
All →Neuronetics Insider Jorey Chernett Buys $79.6K of Stock
Jorey Chernett bought 40,000 shares of Neuronetics, Inc. at $1.99 a share, worth $79.6K in total on Nov 9, 2026. Shares held after the trade: 10,306,225 (+0.4%).
- Value
- $79.6K
- Shares
- 40,000
- Price
- $1.99
- Holding change
- +0.4%
- Trade date
- Nov 9, 2026
Neuronetics Insider Jorey Chernett Sells $4.48M of Stock
Jorey Chernett sold 3,335,411 shares of Neuronetics, Inc. at $1.15 to $2.39 a share (average $1.34) in 5 transactions, worth $4.48M in total between Nov 6, 2026 and Nov 13, 2026. Shares held after the trade: 7,325,577 (-23.0%).
- Value
- $4.48M
- Shares
- 3,335,411
- Average price
- $1.34
- Holding change
- -23.0%
- Trade date
- Nov 6, 2026 to Nov 13, 2026
Neuronetics Capital Raise of $30M
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.
- Value
- $30M
- Counterparty
- William Blair & Company, L.L.C.
Neuronetics Capital Raise of $30M
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.
- Value
- $30M
- Counterparty
- William Blair & Company, L.L.C.
Neuronetics Debt Financing Update with Perceptive Credit Holdings IV, LP
Neuronetics entered into Amendment No. 6 to its existing Credit Agreement with Perceptive Credit Holdings IV, LP to modify certain revenue covenants. The amendment is subject to an optional prepayment of at least $15 million plus interest and fees, and will automatically terminate if conditions are not met by November 30, 2026.
- Counterparty
- Perceptive Credit Holdings IV, LP
Neuronetics Earnings Call: Key Takeaways
Neuronetics reported 9% revenue growth driven by Greenbrook clinics while pivoting Neurostar to a capital-purchase model to address broader market demand and improve profitability.